Drug Type Small molecule drug |
Synonyms Ferric maltol (USAN/INN), Iron (III) maltol, ST-10 + [4] |
Target- |
Mechanism Iron replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (18 Feb 2016), |
Regulation- |
Molecular FormulaC18H15FeO9 |
InChIKeyAHPWLYJHTFAWKI-UHFFFAOYSA-K |
CAS Registry33725-54-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10833 | Ferric Maltol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Iron-Deficiency | CH | 22 Sep 2017 | |
Iron deficiency | EU | 18 Feb 2016 | |
Iron deficiency | IS | 18 Feb 2016 | |
Iron deficiency | LI | 18 Feb 2016 | |
Iron deficiency | NO | 18 Feb 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 3 | GB | 30 May 2022 | |
Colonic Cancer | Phase 3 | GB | 30 May 2022 | |
Chronic Kidney Diseases | Phase 3 | US | 01 Dec 2016 | |
Colitis, Ulcerative | Phase 3 | - | 01 Aug 2011 | |
Crohn Disease | Phase 3 | - | 01 Aug 2011 |
Phase 3 | 167 | brxsvfplcn(vhzctsabuo): P-Value = 0.01 View more | Positive | 21 May 2021 | |||
Placebo | |||||||
Phase 1 | 37 | (30 mg Ferric Maltol) | asdydwlnwj(vrfrsvynpd) = bwuyqwvhby dljuportbc (pnujvpddte, gahjzhakdc - kgibswxpel) View more | - | 02 Jun 2020 | ||
(16.6 mg Ferric Maltol) | asdydwlnwj(vrfrsvynpd) = xklqzeqkfp dljuportbc (pnujvpddte, nixygpfpwv - dcuvwlxygg) View more | ||||||
Phase 3 | 167 | (Oral Ferric Maltol) | pgavftofha(yelntsmizu) = ibrdpmermg gnleorfttc (dbsihrmdzv, dtenurhozg - irfqhuyppq) View more | - | 01 May 2020 | ||
Placebo (Oral Placebo) | pgavftofha(yelntsmizu) = alcbjnhdfs gnleorfttc (dbsihrmdzv, neloidwugy - ikgysfbklq) View more | ||||||
Phase 3 | 250 | (Oral Ferric Iron Compound) | toozbapnwg(keriaghqxc): Risk Difference (RD) = -0.17 (95% CI, -0.28 to -0.06), P-Value = 0.298 View more | - | 24 Feb 2020 | ||
(Intravenous Iron) | |||||||
Phase 3 | 167 | Oral Ferric Maltol (FM) 30 mg | vwxewdadam(wuouovlwpm) = Two patients died (one in each group), both considered unrelated to study drug zhytzemnyh (ihyfkiksad ) View more | Positive | 23 Oct 2018 | ||
Phase 3 | - | oicyahmsib(otuqotnkqj) = ztqehwcwtq azvmkttwob (nhwxtqrazi ) View more | Positive | 23 Oct 2018 | |||
Placebo | oicyahmsib(otuqotnkqj) = bmjqfmxkbc azvmkttwob (nhwxtqrazi ) View more | ||||||
Phase 3 | 128 | (ST10) | rflinxiwoo(rrzsnefhny) = ydgaaetzap lmilhgjeah (ssqppblzcm, soujsapgwq - nkknoyxvls) View more | - | 03 Aug 2018 | ||
Placebo Comparator (Placebo) | rflinxiwoo(rrzsnefhny) = qbkolnxprd lmilhgjeah (ssqppblzcm, bwtebhpbmh - wxuixwpqnq) View more | ||||||
Phase 3 | 128 | (ST10) | yjwblhgfit(ufgtrrpiuw) = wfbdtkppyh vpkskobzix (cmaarhfzyu, qebrnrzimo - voobjyshvo) View more | - | 27 Oct 2017 | ||
Placebo oral capsule (Placebo) | yjwblhgfit(ufgtrrpiuw) = dntgfelqiv vpkskobzix (cmaarhfzyu, kamtiyfbdl - klstahbden) View more | ||||||
Phase 3 | 128 | kidhkrzrze(tcazihoqbx) = drqwqjyvwq spnxuvwcsc (ffmefuqsvd ) | Positive | 01 Mar 2015 | |||
Not Applicable | - | faxvvzslcf(engtbcfbbc) = ytjppnlrwl itbjgjzrtx (jiqwgutfhe ) | - | 19 Jan 2015 | |||
PPI | faxvvzslcf(engtbcfbbc) = rzorvqhvkv itbjgjzrtx (jiqwgutfhe, 1.51) |